Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Single Dose and 28-day Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream 0.5% and 0.15% in Adults With Mild to Moderate Chronic Plaque Psoriasis

NCT03392168 is registered in ClinicalTrials.gov with Arcutis Biotherapeutics, Inc. as lead sponsor.

NCT NCT03392168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03392168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Single Dose and 28-day Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream 0.5% and 0.15% in Adults With Mild to Moderate Chronic Plaque Psoriasis
Lead sponsor
Arcutis Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 11, 2017
Completion date
May 2, 2018
Enrollment
91 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis